Medpace Holdings, Inc. $MEDP Holdings Increased by Ieq Capital LLC

Ieq Capital LLC grew its stake in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 45.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,278 shares of the company’s stock after buying an additional 29,907 shares during the quarter. Ieq Capital LLC’s holdings in Medpace were worth $53,513,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Optiver Holding B.V. bought a new stake in shares of Medpace during the 3rd quarter worth about $27,000. Steigerwald Gordon & Koch Inc. bought a new stake in shares of Medpace during the 4th quarter worth about $30,000. Elyxium Wealth LLC bought a new stake in shares of Medpace during the 4th quarter worth about $30,000. Quarry LP bought a new stake in shares of Medpace during the 3rd quarter worth about $35,000. Finally, Core Wealth Advisors LLC bought a new stake in shares of Medpace during the 4th quarter worth about $47,000. 77.98% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have commented on MEDP. Wall Street Zen downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research report on Saturday, April 25th. Robert W. Baird dropped their price target on shares of Medpace from $565.00 to $477.00 and set an “outperform” rating on the stock in a research report on Friday, April 24th. Royal Bank Of Canada lowered their price objective on shares of Medpace from $522.00 to $484.00 and set an “outperform” rating on the stock in a research note on Friday, April 24th. Weiss Ratings cut shares of Medpace from a “buy (b-)” rating to a “hold (c+)” rating in a research note on Monday, April 6th. Finally, Barclays lowered their price objective on shares of Medpace from $500.00 to $450.00 and set an “equal weight” rating on the stock in a research note on Friday, April 24th. Four research analysts have rated the stock with a Buy rating, ten have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $467.08.

Medpace Price Performance

Shares of MEDP opened at $467.34 on Friday. The firm’s 50 day moving average is $456.43 and its 200-day moving average is $504.64. The stock has a market capitalization of $13.35 billion, a P/E ratio of 29.37, a P/E/G ratio of 2.41 and a beta of 1.18. Medpace Holdings, Inc. has a 12-month low of $294.07 and a 12-month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings data on Wednesday, April 22nd. The company reported $4.28 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.74 by $0.54. The company had revenue of $706.60 million for the quarter, compared to analysts’ expectations of $697.82 million. Medpace had a net margin of 17.19% and a return on equity of 120.89%. The business’s revenue was up 26.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. As a group, equities research analysts forecast that Medpace Holdings, Inc. will post 17.04 EPS for the current fiscal year.

Insider Activity at Medpace

In other news, General Counsel Stephen P. Ewald sold 16,349 shares of Medpace stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the transaction, the general counsel directly owned 20,343 shares of the company’s stock, valued at $9,154,350. This trade represents a 44.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, President Jesse J. Geiger sold 31,707 shares of Medpace stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $455.30, for a total transaction of $14,436,197.10. Following the completion of the transaction, the president directly owned 15,000 shares in the company, valued at approximately $6,829,500. This trade represents a 67.88% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 20.50% of the company’s stock.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.